Logo     Print Page  Close Window


News, Events & Presentations


Press Releases | Events Calendar | Presentations

Keyword Search
 
2018 | 2017 | 2016 | 2015
DateTitle 
09/26/18Fibrocell to Present at Upcoming Industry and Investor ConferencesPrinter Friendly Version
09/25/18Fibrocell Awarded $1.4 Million FDA Orphan Grant for FCX-007 for Treatment of Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
09/05/18Fibrocell Announces FDA Fast Track Designation of FCX-013 for Treatment of Moderate to Severe Localized SclerodermaPrinter Friendly Version
08/29/18Fibrocell to Present at 20th Annual Rodman & Renshaw Global Investment ConferencePrinter Friendly Version
08/09/18Fibrocell Reports Second Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
08/02/18Fibrocell to Host Conference Call and Webcast on Thursday, August 9, 2018 to Discuss Second Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
07/05/18Fibrocell Announces Closing of $4.0 Million Registered Direct OfferingPrinter Friendly Version
07/02/18Fibrocell Announces $4.0 Million Registered Direct Offering Priced At-the-MarketPrinter Friendly Version
05/31/18Fibrocell Announces Closing of $6.0 Million Registered Direct OfferingPrinter Friendly Version
05/29/18Fibrocell Announces $6.0 Million Registered Direct Offering Priced At-the-MarketPrinter Friendly Version
05/24/18Fibrocell Announces One-for-Five Reverse Stock SplitPrinter Friendly Version
05/21/18Fibrocell Reports on Interim Results and Progress of Phase 1/2 Clinical Trial of FCX-007 Gene Therapy for Recessive Dystrophic Epidermolysis BullosaPrinter Friendly Version
05/16/18Fibrocell Announces Oral Presentation at 7th International Investigative Dermatology MeetingPrinter Friendly Version
05/10/18Fibrocell Reports First Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
05/03/18Fibrocell to Host Conference Call and Webcast on Thursday, May 10, 2018 to Discuss First Quarter 2018 Financial Results and Recent HighlightsPrinter Friendly Version
04/18/18Fibrocell Announces Review of Strategic AlternativesPrinter Friendly Version
04/10/18Fibrocell to Present at 6th Annual Cell & Gene Therapy Investor Day and 2018 World Orphan Drug Congress USAPrinter Friendly Version
03/19/18Fibrocell Reports 2017 Financial Results and Recent HighlightsPrinter Friendly Version
03/12/18Fibrocell to Host Conference Call and Webcast on Monday, March 19, 2018 to Discuss 2017 Financial Results and Recent HighlightsPrinter Friendly Version
03/06/18Fibrocell Announces FDA Allowance of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized SclerodermaPrinter Friendly Version
02/06/18Fibrocell to Present at 20th Annual BIO CEO & Investor ConferencePrinter Friendly Version
02/05/18Fibrocell Announces Submission of Investigational New Drug Application for FCX-013 for the Treatment of Moderate to Severe Localized SclerodermaPrinter Friendly Version
01/30/18Fibrocell Announces FDA Allowance to Initiate Pediatric Enrollment in Phase 1/2 Clinical Trial of FCX-007 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)Printer Friendly Version
01/24/18Fibrocell to Present at Phacilitate Cell and Gene Therapy World 2018 Printer Friendly Version